Mature Giant vs. High-Growth Biotech Pioneer: Amgen and Vertex Pharmaceuticals

Amgen and Vertex Pharmaceuticals represent two contrasting approaches in the US biotech sector. Amgen, a mature pharmaceutical powerhouse, has a diversified portfolio across oncology, inflammation, and rare disease therapeutics, serving a broad patient base worldwide.

In fiscal 2025, Amgen reported total revenue of nearly $36.7 billion, a year-over-year increase of roughly 9.9%, with net income climbing to approximately $7.7 billion and a net margin of about 21%. The company offers a stable shareholder payout, with an annual dividend of $9.94 representing a 2.63% dividend yield.

Vertex Pharmaceuticals, on the other hand, has built a unique franchise in cystic fibrosis care, leveraging rare disease specialization and robust pricing power. In fiscal 2025, Vertex generated revenue of nearly $12.1 billion, up approximately 9.6% year over year, with net income reaching roughly $4.0 billion and an 86.12% gross margin.

The choice between these two companies ultimately comes down to a trade-off: steady, scale-driven reliability versus high-growth, high-margin upside. Amgen's risk landscape is shaped by the headwinds common to large, established pharma companies, including pricing and patent expiration pressures, customer concentration, and supply chain vulnerability.

Vertex, while trading at a higher valuation and carrying greater single-segment concentration risk, offers a compelling growth proposition with dominant market share in cystic fibrosis, a rapidly scaling gene therapy franchise, expansion into new therapeutic areas, industry-leading margins, and a fortress balance sheet.